LNPs that are potent in vitro but often not in vivo, therefore it is necessary to optimize in order to have a functional platform for drug delivery and clinical translation. Important! tiny changes in the lipid molecules of LNPs can result in a 1000-fold higher delivery! #NVGCT2025

Last pitch comes from Tessa Prins (ExoVectory), Federico Cocozza (Utrecht University) and Despoina Trasanidou (Sanquin) who combine their expertise and passion into one project. The final winner will be announced at the end of the meeting! Congratulations to all the participants!! #NVGCT2025 #ZonMw

Next in line are Stefan Kint and Grigory Kornienko from #Exovectory and #Amsterdamumc @amsterdamumc.bsky.social, respectively

This work highlights how a therapy was developed in 8 months! This poses chances for a platform for n-of-1 studies, however the conventional drug development is way longer, at least in the EU. Can this be sped up?

To end, he give the look to the future. Once again, congratulations to Prof. Vincenzo Cerullo for receiving this NVGCT award for his contribution to the field! #NVGCT2025 #award #oncolyticvirus #peptides #cancer

for that a peptichip was created as otherwise many cells were needed. Still after finding the peptides they need to be tested for immunogenicity

while generating a batch of virus is very expensive. So in that sense having a regular virus decorated with peptides decreases the price. But how to find these peptides?

Other examples are PeptiENV (using again oncolytic viruses) or PeptiBAC (using Bacteria) modified with the peptides. By combining peptides with the virus or bacteria you can make the product cheaper because generating the peptide to decorate the virus is very cheap and controlled

So basically an oncolytic virus has become an anti-tummor vaccine, steering the Ferrari in the desired direction. The delivery also was improved to deliver subcutaneously and intratumoral, developing a stronger response. The results of the clinical trial will be presented at the #ESGCT 2025

Oncolytic viruses are good vehicles but need improvements. Prof. Cerullo has been guiding us on how to built these viruses by comparing them to a Ferrari. But how he did that? For example by anchoring a tumor-specific peptide, which led to PeptiCRAd (currently in clinical trials).

However, before starting his presentations he had a clear message to the quizzmasters of the famous NVGCT pubquiz "Ricotta is a fantastic cheese but is not included in Lasagna or Pasta Alfredo" Statement from an Italian-dominated team #NVGCT2025

@olivier-de-jong.bsky.social